PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.07
0.06 - 0.24
1.89M / 3.59M (Avg.)
-1.60 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
43.03%
EBIT growth above 1.5x CRN.AX's 19.60%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
43.03%
Positive operating income growth while CRN.AX is negative. John Neff might view this as a competitive edge in operations.
98.33%
Net income growth above 1.5x CRN.AX's 47.33%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
98.37%
EPS growth above 1.5x CRN.AX's 47.22%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
98.37%
Diluted EPS growth above 1.5x CRN.AX's 47.31%. David Dodd would see if there's a robust moat protecting these shareholder gains.
4.91%
Slight or no buybacks while CRN.AX is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
4.91%
Diluted share change of 4.91% while CRN.AX is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
59.77%
OCF growth under 50% of CRN.AX's 11374.81%. Michael Burry might suspect questionable revenue recognition or rising costs.
58.01%
FCF growth 50-75% of CRN.AX's 113.93%. Martin Whitman would see if structural disadvantages exist in generating free cash.
-100.00%
Negative 10Y revenue/share CAGR while CRN.AX stands at 0.00%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-100.00%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-100.00%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
51.86%
OCF/share CAGR of 51.86% while CRN.AX is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
51.86%
Positive OCF/share growth while CRN.AX is negative. John Neff might see a comparative advantage in operational cash viability.
51.86%
Positive 3Y OCF/share CAGR while CRN.AX is negative. John Neff might see a big short-term edge in operational efficiency.
98.82%
10Y net income/share CAGR of 98.82% while CRN.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
98.82%
Positive 5Y CAGR while CRN.AX is negative. John Neff might view this as a strong mid-term relative advantage.
98.82%
Positive short-term CAGR while CRN.AX is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.76%
Positive asset growth while CRN.AX is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-1.39%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-73.75%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.